Disc Medicine (NASDAQ:IRON) Posts Earnings Results, Beats Estimates By $0.07 EPS

Disc Medicine (NASDAQ:IRON) announced its quarterly earnings results on Thursday. The company reported ($1.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07, FiscalAI reports. The firm had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million.

Disc Medicine Stock Performance

Shares of IRON stock traded down $1.29 on Friday, reaching $66.62. The stock had a trading volume of 345,062 shares, compared to its average volume of 966,395. The stock has a market cap of $2.51 billion, a P/E ratio of -11.12 and a beta of 0.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. The company has a 50 day simple moving average of $74.43 and a 200 day simple moving average of $75.40. Disc Medicine has a 1 year low of $30.82 and a 1 year high of $99.50.

Insiders Place Their Bets

In other news, Director Kevin Bitterman sold 68,923 shares of Disc Medicine stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $91.24, for a total value of $6,288,534.52. Following the completion of the transaction, the director owned 14,161 shares in the company, valued at approximately $1,292,049.64. The trade was a 82.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rahul Khara sold 6,500 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $78.69, for a total value of $511,485.00. Following the transaction, the insider directly owned 37,793 shares in the company, valued at approximately $2,973,931.17. This represents a 14.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 285,114 shares of company stock valued at $24,937,862. Insiders own 3.64% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its position in shares of Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares in the last quarter. RA Capital Management L.P. lifted its holdings in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after acquiring an additional 399,026 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Disc Medicine by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock worth $134,839,000 after buying an additional 371,576 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Disc Medicine by 257.1% in the 3rd quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock valued at $33,040,000 after purchasing an additional 360,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Disc Medicine in the third quarter valued at approximately $22,342,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Trending Headlines about Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Beat on quarterly results — Disc reported Q4 and full‑year 2025 results with EPS of ($1.62), beating consensus (($1.69)) and provided a business update; the small earnings beat is a short‑term positive signal for execution and guidance clarity. Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst target lowered but rating sustained — Truist cut its price target from $114 to $83 but kept a “buy” rating, signalling continued analyst confidence in the longer‑term thesis despite reduced near‑term expectations. Truist lowers price target to $83
• Neutral Sentiment: Insider sale by CFO — CFO Jean M. Franchi sold 353 shares at ~$69; the sale is small (0.49% reduction in her holdings) and appears routine rather than a clear signal of negative private information. CFO insider sale filing
• Neutral Sentiment: Short‑interest report is inconclusive — a MarketBeat entry shows anomalous/zero short interest data for February (days‑to‑cover 0.0), so there’s no clear short‑squeeze or elevated short pressure signal from this report.
• Negative Sentiment: Restructuring after FDA response — Disc’s board approved a restructuring following an FDA response, implying a regulatory/setback event that prompted corporate changes; this raises near‑term execution and timeline uncertainty for pipeline programs. Disc Medicine Implements Restructuring Following FDA Response
• Negative Sentiment: Investor litigation alert — Pomerantz LLP announced an investigation into Disc Medicine, which can increase legal risk, potential distraction, and perceived governance concerns among investors. Pomerantz investigates Disc Medicine

Analyst Ratings Changes

IRON has been the topic of a number of recent research reports. Morgan Stanley set a $75.00 price objective on shares of Disc Medicine in a report on Tuesday, February 17th. Raymond James Financial reiterated a “market perform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. UBS Group reaffirmed an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Truist Financial dropped their target price on Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a report on Friday. Finally, BMO Capital Markets dropped their target price on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 17th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $102.00.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.